CA2398445C - A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome - Google Patents

A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome Download PDF

Info

Publication number
CA2398445C
CA2398445C CA2398445A CA2398445A CA2398445C CA 2398445 C CA2398445 C CA 2398445C CA 2398445 A CA2398445 A CA 2398445A CA 2398445 A CA2398445 A CA 2398445A CA 2398445 C CA2398445 C CA 2398445C
Authority
CA
Canada
Prior art keywords
stevioside
treatment
insulin
use according
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2398445A
Other languages
English (en)
French (fr)
Other versions
CA2398445A1 (en
Inventor
Kjeld Hermansen
Soren Gregersen
Per Bendix Jeppesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stevia ApS
Original Assignee
Stevia ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stevia ApS filed Critical Stevia ApS
Priority to CA2762121A priority Critical patent/CA2762121A1/en
Publication of CA2398445A1 publication Critical patent/CA2398445A1/en
Application granted granted Critical
Publication of CA2398445C publication Critical patent/CA2398445C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/62—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings
    • C07C13/66—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings
    • C07C13/68—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with more than three condensed rings the condensed ring system contains only four rings with a bridged ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/35—Unsaturated compounds having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2398445A 2000-02-01 2001-02-01 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome Expired - Fee Related CA2398445C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2762121A CA2762121A1 (en) 2000-02-01 2001-02-01 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000163 2000-02-01
DKPA200000163 2000-02-01
PCT/DK2001/000075 WO2001056959A1 (en) 2000-02-01 2001-02-01 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2762121A Division CA2762121A1 (en) 2000-02-01 2001-02-01 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome

Publications (2)

Publication Number Publication Date
CA2398445A1 CA2398445A1 (en) 2001-08-09
CA2398445C true CA2398445C (en) 2012-04-03

Family

ID=8159060

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2398445A Expired - Fee Related CA2398445C (en) 2000-02-01 2001-02-01 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
CA2762121A Abandoned CA2762121A1 (en) 2000-02-01 2001-02-01 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2762121A Abandoned CA2762121A1 (en) 2000-02-01 2001-02-01 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome

Country Status (8)

Country Link
US (5) US20030060428A1 (https=)
EP (2) EP1255718A1 (https=)
JP (2) JP2003521528A (https=)
CN (1) CN100475757C (https=)
AU (1) AU784422B2 (https=)
BR (1) BR0108043A (https=)
CA (2) CA2398445C (https=)
WO (1) WO2001056959A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521528A (ja) 2000-02-01 2003-07-15 ステヴィア，エイプス 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び／又は代謝症候群の治療のための薬剤の調製に使用する物質
BRPI0412189A (pt) * 2003-06-30 2006-08-22 Nestec Sa composição para tratar e/ou prevenir disfunções associadas à diabetes melito do tipo 2
AT502270B1 (de) * 2005-02-21 2007-07-15 Emakos Naturnahe Nahrungsmitte Verfahren zum modifizieren von steviosid durch austauschreaktionen
US8956677B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with glucosamine and compositions sweetened therewith
KR20080071606A (ko) * 2005-11-23 2008-08-04 더 코카콜라 컴파니 시간 특성 및/또는 향미 특성이 개선된 인공 감미료조성물과 이들의 제제 방법 및 용도
US9144251B2 (en) * 2005-11-23 2015-09-29 The Coca-Cola Company High-potency sweetener composition with mineral and compositions sweetened therewith
AU2006318781B2 (en) * 2005-11-23 2012-11-01 The Coca-Cola Company Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
US8940350B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Cereal compositions comprising high-potency sweeteners
US20070116831A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company Dental Composition with High-Potency Sweetener
US8524304B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith
US8956678B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with preservative and compositions sweetened therewith
US8993027B2 (en) * 2005-11-23 2015-03-31 The Coca-Cola Company Natural high-potency tabletop sweetener compositions with improved temporal and/or flavor profile, methods for their formulation, and uses
US8524303B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with phytosterol and compositions sweetened therewith
US20070134391A1 (en) * 2005-11-23 2007-06-14 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith
US8940351B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Baked goods comprising high-potency sweetener
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US20070116836A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith
US8367138B2 (en) * 2005-11-23 2013-02-05 The Coca-Cola Company Dairy composition with high-potency sweetener
US20070116822A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-potency sweetener composition with saponin and compositions sweetened therewith
EP2380566A3 (en) * 2006-09-15 2012-04-11 Stevia APS Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US9101161B2 (en) * 2006-11-02 2015-08-11 The Coca-Cola Company High-potency sweetener composition with phytoestrogen and compositions sweetened therewith
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
MY155722A (en) * 2007-12-03 2015-11-30 Dsm Ip Assets Bv Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof
WO2009071099A1 (en) * 2007-12-05 2009-06-11 Aarhus Universitet Elevation of the plasma hdl-cholesterol level
US8759405B2 (en) * 2009-07-21 2014-06-24 Dsm Ip Assets B.V. Stevia extract or steviol for hair care
WO2011033524A2 (en) 2009-08-04 2011-03-24 Laila Nutraceuticals Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases
US20110189360A1 (en) * 2010-02-04 2011-08-04 Pepsico, Inc. Method to Increase Solubility Limit of Rebaudioside D in an Aqueous Solution
WO2012127287A2 (en) * 2011-03-18 2012-09-27 Febris Bio-Tech Limited Compositions and methods for treating multi-drug resistant malaria
EP2988754A1 (en) 2013-04-23 2016-03-02 Aarhus Universitet Compositions for use in restoring muscle glycogen and/or muscle mass
RU2525593C1 (ru) * 2013-05-24 2014-08-20 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации Способ комплексного лечения артериальной гипертонии при метаболических нарушениях
TWI516474B (zh) 2013-05-27 2016-01-11 中央研究院 良薑化合物及其類似物之合成
AU2014279129B2 (en) 2013-06-10 2018-07-12 Suntory Holdings Limited Plant extract containing diketopiperazine and method for producing same
SG11201800675PA (en) * 2015-07-27 2018-02-27 Suntory Holdings Ltd Composition containing cyclic dipeptide and sweetening agent
CA3015700A1 (en) * 2015-09-10 2017-03-16 Key-Pharma Biomedical Inc. The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension
MX2019004534A (es) 2016-10-20 2019-10-02 Coca Cola Co Glicosidos de diterpénicos aislados a partir de stevia, composiciones y métodos.
CN108159034B (zh) * 2018-02-12 2019-10-11 东南大学 异甜菊醇在制备治疗非酒精性脂肪性肝病药物中的应用
WO2020218382A1 (ja) * 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Ｇｌｐ－１分泌促進剤
CN111357979A (zh) * 2019-12-26 2020-07-03 浙江欧谱生物科技有限公司 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用
CN111233702A (zh) * 2020-01-20 2020-06-05 中国科学院昆明植物研究所 先花铃子香素a衍生物与其药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626441B1 (en) * 1983-10-06 1991-02-19 Dietetic frozen desserts containing aspartame
JPS63146813A (ja) * 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk ジテルペン系化合物を含んで成る制癌剤
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
JPH0813251B2 (ja) * 1993-07-14 1996-02-14 長岡香料株式会社 鉄及び又はマグネシウム及び又はカルシウムを含む呈味改善液
CN1094580A (zh) * 1994-01-06 1994-11-09 贾玉海 降糖糊
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JPH08325156A (ja) * 1995-06-01 1996-12-10 Ichimaru Pharcos Co Ltd ステビオール配糖体含有皮膚外用剤及び飲食品
JPH0952825A (ja) * 1995-06-09 1997-02-25 Taisho Pharmaceut Co Ltd 解熱鎮痛剤
CN1148476A (zh) * 1995-10-20 1997-04-30 王国安 一种降糖保健食品添加剂及其配制方法
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
CN1065753C (zh) * 1996-12-04 2001-05-16 上海绿泰宝营养保健品有限公司 降糖冲剂及其制备方法
CN1062722C (zh) * 1997-04-04 2001-03-07 青岛海洋大学 双纤维降糖粉及其制造方法
AU7906898A (en) * 1997-06-13 1998-12-30 Novo Nordisk A/S Novel niddm regimen
US5980902A (en) * 1998-03-26 1999-11-09 Pharma Terra, Inc. Compositions for treating and preventing diabetes, impaired glucose tolerance and related symptoms, and methods for preparing and using such compositions
ATE264093T1 (de) * 1998-07-16 2004-04-15 Aaron Tabor Sojazubereitungen und deren verwendung zur gesundheitsförderung
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
JP2003521528A (ja) 2000-02-01 2003-07-15 ステヴィア，エイプス 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び／又は代謝症候群の治療のための薬剤の調製に使用する物質
EP1361870A2 (en) 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US20090232913A1 (en) 2005-05-02 2009-09-17 Momir Mikov Composition for the Control of Cholesterol Levels
WO2007047803A2 (en) * 2005-10-20 2007-04-26 Ghc Research Development Corporation Use of prolactin in the prophylactic treatment of cancer
EP2380566A3 (en) * 2006-09-15 2012-04-11 Stevia APS Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener

Also Published As

Publication number Publication date
CN1416411A (zh) 2003-05-07
WO2001056959A1 (en) 2001-08-09
CA2398445A1 (en) 2001-08-09
EP1255718A1 (en) 2002-11-13
US20080318866A1 (en) 2008-12-25
JP2012153721A (ja) 2012-08-16
EP2330092A3 (en) 2012-07-25
AU3002801A (en) 2001-08-14
WO2001056959B1 (en) 2002-02-07
US9636314B2 (en) 2017-05-02
AU784422B2 (en) 2006-03-30
JP2003521528A (ja) 2003-07-15
US20080051341A1 (en) 2008-02-28
US20030060428A1 (en) 2003-03-27
US20140094408A1 (en) 2014-04-03
CN100475757C (zh) 2009-04-08
CA2762121A1 (en) 2001-08-09
US20050038126A1 (en) 2005-02-17
EP2330092A2 (en) 2011-06-08
BR0108043A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
CA2398445C (en) A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US20040081712A1 (en) Substance for treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
Matsuda et al. Inhibition of gastric emptying by triterpene saponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system
US8404746B2 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
US7674486B2 (en) Synergistic composition for the treatment of diabetes mellitus
Ray et al. Effects of Stevia rebaudiana on glucose homeostasis, blood pressure and inflammation: a critical review of past and current research evidence
BRPI0822169A2 (pt) uma composição e um processo da mesma
KR20090081860A (ko) 가공된 알로에 베라 겔을 포함하는 제2형 당뇨병 치료용의약 조성물
US5851531A (en) Adult-onset diabetes treatment method
US9566308B2 (en) Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus
HK1156930A (en) Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US6562379B2 (en) Adult-onset diabetes treatment method
KR100473529B1 (ko) 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물
US7736676B2 (en) Synergistic composition for the treatment of diabetes mellitus
JP2004532808A (ja) コショウ科キンマリーフエキスの抗単球活性
KR102291168B1 (ko) 부들 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물
Sudha et al. ANTIDIABETIC AND ANTIHYPERLIPIDEMIC EFFECT OF ETHANOLIC
KR100478150B1 (ko) 생약 복합제 추출물을 유효성분으로 함유하는 당뇨병 예방용 건강보조식품
US20040071803A1 (en) Process for preparation of anti-diabetic compositions from banyan bark
BR102018015260A2 (pt) composição e formulação farmacêutica para o tratamento da diabetes e doenças metabólicas a partir de extratos de cnidoscolus quercipholius pohl (faveleira)
Chandralekha et al. ANTIDIABETIC ACTIVITY AND PHYTOCHEMICAL SCREENING OF LEAVES EXTRACT OF DIOSPYROS PEREGRINE IN ALLOXAN-INDUCED DIABETIC RATS
KR20200119939A (ko) 세리포리아 라세라타 균사체 추출물을 함유하는 약학적 조성물 및 건강기능식품

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170201